Detalhe da pesquisa
1.
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials.
Gastroenterology
; 2024 May 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38788861
2.
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Clin Gastroenterol Hepatol
; 22(4): 810-820.e7, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37806372
3.
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Gastroenterology
; 160(7): 2340-2353, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33676969
4.
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.
BMJ Open Gastroenterol
; 11(1)2024 Feb 08.
Artigo
Inglês
| MEDLINE | ID: mdl-38336367